首页> 外文期刊>Cardiovascular drugs and therapy >Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?
【24h】

Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?

机译:Personalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective?

获取原文
获取原文并翻译 | 示例
           

著录项

  • 来源
    《Cardiovascular drugs and therapy》 |2017年第1期|1-3|共3页
  • 作者单位

    Mayo Clin, Kern Ctr Sci Healthcare Delivery, Econ Evaluat Serv, Rochester, MN USA;

    Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Dept Cardiovasc Dis, Rochester, MN USA;

    Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 药学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号